trending Market Intelligence /marketintelligence/en/news-insights/trending/y_m4opmt2fvxa8ou94pmvq2 content esgSubNav
In This List

Galmed Pharmaceuticals names class II director

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Galmed Pharmaceuticals names class II director

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, appointed Marshall Heinberg as its class II director.

Heinberg is a senior adviser to Burford Capital and is the founder and managing director of MAH Associates LLC, which provides strategic advisory and consulting services to various companies. Heinberg will serve as board member until the company's 2019 annual general shareholders meeting.

Tel Aviv, Israel-based Galmed Pharmaceuticals develops therapeutics to treat liver diseases.